Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

11/12/2021 | 08:31am EST

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences.

Cowen's 5th Annual IO Next Summit
Monday, November 15, 2021
8:45 AM PT/11:45 AM ET

Stifel 2021 Virtual Healthcare Conference
Tuesday, November 16, 2021
11:00 AM PT/2:00 PM ET

Jefferies London Healthcare Conference
Thursday, November 18, 2021
Pre-recorded session available starting at 1:00 AM PT/8:00 AM GMT

Evercore ISI 4th Annual HealthCONx Conference
Tuesday, November 30, 2021
12:30 PM PT/3:30 PM ET

The JMP Securities Hematology and Oncology Summit
Monday, December 6, 2021
12:00 PM PT/3:00 PM ET

Webcasts will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended September 30, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com


All news about ALLOGENE THERAPEUTICS, INC.
08:31aAllogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Confere..
GL
01/18Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical H..
AQ
01/14INSIDER BUY : Allogene Therapeutics
MT
01/12Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11ALLOGENE THERAPEUTICS : JPM Presentation 2022
PU
01/11Allogene Therapeutics Enters Into Cancer Therapy Collaboration With Antion Biosciences
MT
01/11Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clini..
AQ
01/11Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
AQ
01/11Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical ..
AQ
01/11US FDA Lifts Hold on Cellectis Partner's Clinical Studies of Cancer Therapy
MT
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 38,4 M - -
Net income 2021 -265 M - -
Net cash 2021 492 M - -
P/E ratio 2021 -5,71x
Yield 2021 -
Capitalization 1 599 M 1 599 M -
EV / Sales 2021 28,8x
EV / Sales 2022 436x
Nbr of Employees 301
Free-Float -
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 11,22 $
Average target price 32,38 $
Spread / Average Target 189%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-23.86%1 619
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-12.11%50 700
BIONTECH SE-39.30%37 796